Fluorescein (Ophthalmic)

Adult Indications & Dosage
Pediatric Indications & Dosage
Contraindications
Warnings & Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Administration & Monitoring
Overdosage
Pharmacology
Clinical Studies
How Supplied
Images
Patient Counseling Information
Precautions with Alcohol
Brand Names
Look-Alike Names

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:  Ammu Susheela, M.D. [2]

## Disclaimer

WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.

## Overview

Fluorescein (Ophthalmic) is a contrast media that is FDA approved for the diagnosis of for testing tear film stability by determining the fluorescein break-up time (FBUT). Common adverse reactions include hypersensitivity.

## Adult Indications and Dosage

### FDA-Labeled Indications and Dosage (Adult)

##### Indication

* For testing tear film stability by determining the fluorescein break-up time (FBUT).

### Off-Label Use and Dosage (Adult)

#### Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Fluorescein (Ophthalmic) in adult patients.

#### Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Fluorescein (Ophthalmic) in adult patients.

## Pediatric Indications and Dosage

### FDA-Labeled Indications and Dosage (Pediatric)

There is limited information regarding FDA-Labeled Use of Fluorescein (Ophthalmic) in pediatric patients.

### Off-Label Use and Dosage (Pediatric)

#### Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Fluorescein (Ophthalmic) in pediatric patients.

#### Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Fluorescein (Ophthalmic) in pediatric patients.

## Contraindications

* Hypersensitivity to components or mercury-containing compounds.

## Warnings

There is limited information regarding Fluorescein (Ophthalmic) Warnings' in the drug label.

## Adverse Reactions

### Clinical Trials Experience

There is limited information regarding Clinical Trial Experience of Fluorescein (Ophthalmic) in the drug label.

### Postmarketing Experience

* Hypersensitivity

## Drug Interactions

There is limited information regarding Fluorescein (Ophthalmic) Drug Interactions in the drug label.

## Use in Specific Populations

#### Pregnancy

Pregnancy Category (FDA): C

* Pregnancy Category

Pregnancy Category (AUS):

* Australian Drug Evaluation Committee (ADEC) Pregnancy Category

There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Fluorescein (Ophthalmic) in women who are pregnant.

#### Labor and Delivery

There is no FDA guidance on use of Fluorescein (Ophthalmic) during labor and delivery.

#### Nursing Mothers

There is no FDA guidance on the use of Fluorescein (Ophthalmic) with respect to nursing mothers.

#### Pediatric Use

There is no FDA guidance on the use of Fluorescein (Ophthalmic) with respect to pediatric patients.

#### Geriatic Use

There is no FDA guidance on the use of Fluorescein (Ophthalmic) with respect to geriatric patients.

#### Gender

There is no FDA guidance on the use of Fluorescein (Ophthalmic) with respect to specific gender populations.

#### Race

There is no FDA guidance on the use of Fluorescein (Ophthalmic) with respect to specific racial populations.

#### Renal Impairment

There is no FDA guidance on the use of Fluorescein (Ophthalmic) in patients with renal impairment.

#### Hepatic Impairment

There is no FDA guidance on the use of Fluorescein (Ophthalmic) in patients with hepatic impairment.

#### Females of Reproductive Potential and Males

There is no FDA guidance on the use of Fluorescein (Ophthalmic) in women of reproductive potentials and males.

#### Immunocompromised Patients

There is no FDA guidance one the use of Fluorescein (Ophthalmic) in patients who are immunocompromised.

## Administration and Monitoring

#### Administration

* Ophthalmic

#### Monitoring

There is limited information regarding Monitoring of Fluorescein (Ophthalmic) in the drug label.

## IV Compatibility

There is limited information regarding IV Compatibility of Fluorescein (Ophthalmic) in the drug label.

## Overdosage

There is limited information regarding Fluorescein (Ophthalmic) overdosage. If you suspect drug poisoning or overdose, please contact the National Poison Help hotline (1-800-222-1222) immediately.

## Pharmacology

This image is provided by the National Library of Medicine.

### Mechanism of Action

* Fluorescein sodium responds to electromagnetic radiation and light between the wavelengths of 465-490 nm and fluoresces, i.e., emits light at wavelengths of 520-530 nm. Thus, the hydrocarbon is excited by blue light and emits light that appears yellowish-green. Following intravenous injection of fluorescein sodium in an aqueous solution, the unbound fraction of the fluorescein can be excited with a blue light flash from a fundus camera as it circulates through the ocular vasculature, and the yellowish green fluorescence of the dye is captured by the camera. In the fundus, the fluorescence of the dye demarcates the retinal and/or choroidal vasculature under observation, distinguishing it from adjacent areas/structures.

### Structure

This image is provided by the National Library of Medicine.

### Pharmacodynamics

There is limited information regarding Pharmacodynamics of Fluorescein (Ophthalmic) in the drug label.

### Pharmacokinetics

There is limited information regarding Pharmacokinetics of Fluorescein (Ophthalmic) in the drug label.

### Nonclinical Toxicology

There is limited information regarding Nonclinical Toxicology of Fluorescein (Ophthalmic) in the drug label.

## Clinical Studies

There is limited information regarding Clinical Studies of Fluorescein (Ophthalmic) in the drug label.

## How Supplied

* Carton of 50 pouches of two strips each.

### Storage

There is limited information regarding Fluorescein (Ophthalmic) Storage in the drug label.

## Images

### Drug Images

### Package and Label Display Panel

This image is provided by the National Library of Medicine. This image is provided by the National Library of Medicine.

## Patient Counseling Information

There is limited information regarding Patient Counseling Information of Fluorescein (Ophthalmic) in the drug label.

## Precautions with Alcohol

* Alcohol-Fluorescein (Ophthalmic) interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.

## Brand Names

* DRY EYE TEST®[1]

## Look-Alike Drug Names

There is limited information regarding Fluorescein (Ophthalmic) Look-Alike Drug Names in the drug label.

## Drug Shortage Status

## Price

## References

The contents of this FDA label are provided by the National Library of Medicine.

1. ↑ "DRY EYE TEST- fluorescein sodium strip".